Last reviewed · How we verify
Flutron (DOXIFLURIDINE)
Doxifluridine (Flutron) is a marketed drug indicated for primary malignant neoplasms of the gastrointestinal tract, operating through the inhibition of thymidylate synthase. Its key competitive advantage lies in its unique mechanism of action and the patent protection extending until 2028, providing a barrier to generic entry. The primary risk is the strong competition from off-patent drugs with the same target, such as capecitabine, floxuridine, and fluorouracil, which are widely available and cost-effective alternatives.
At a glance
| Generic name | DOXIFLURIDINE |
|---|---|
| Drug class | doxifluridine |
| Target | Thymidylate synthase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Primary malignant neoplasm of gastrointestinal tract
Common side effects
Key clinical trials
- Trial of Adjuvant Chemotherapy for Gastric Cancer (PHASE3)
- Yttrium Y 90 Glass Microspheres and Capecitabine in Treating Patients With Liver Cholangiocarcinoma or Liver Metastases (PHASE1)
- Trial of Adjuvant Chemotherapy for Gastric Cancer (PHASE3)
- Chemotherapeutic Agents in Brain/Breast
- RCT With Adjuvant Mistletoe Treatment in Gastric Cancer Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Flutron CI brief — competitive landscape report
- Flutron updates RSS · CI watch RSS